GlassScriptPhysician profile
Catherine M Tisdall
NPI 1871556506
$17,934.88
in general payments reported to CMS, 2019-2025
43 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,401 · 2020: $1,178 · 2021: $2,893 · 2022: $2,153 · 2023: $2,632 · 2024: $1,968 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,223 · Education: $85.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,223.15 |
| Education | $85.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,616.68 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $2,392.52 | 2019-2025 | Skyrizi, Rinvoq |
| Almirall LLC | $1,267.37 | 2020-2025 | Seysara, Klisyri |
| Galderma Laboratories, L.P. | $1,219.54 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $960.65 | 2019-2025 | |
| Lilly USA, LLC | $884.00 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $880.40 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $692.86 | 2022-2025 | Opzelura |
| Allergan, INC. | $578.50 | 2019-2022 | |
| Merz North America, INC. | $571.41 | 2019-2021 | |
| Amgen INC. | $560.11 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $529.00 | 2019-2025 | Jublia, Siliq |
| Regeneron Healthcare Solutions, INC. | $526.97 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $487.26 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Scientific Affairs, LLC | $467.19 | 2019-2025 | Tremfya |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Tisdall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.